Want to see CAPR full AI Analyst Report?
CAPR Stock Chart & Stats
$8.29
-$12.67(-64.31%)
At close: 4:00 PM EDT
$8.29
-$12.67(-64.31%)
Day’s Range― - ―
52-Week Range$2.96 - $40.37
Previous CloseN/A
Volume8.05M
Average Volume (3M)3.28M
Market Cap
$390.11M
Enterprise Value$1.25B
Total Cash (Recent Filing)$237.93M
Total Debt (Recent Filing)$91.05M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Nov 17, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding58,138,990
10 Day Avg. Volume2,892,527
30 Day Avg. Volume3,275,116
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.39
Price to Sales (P/S)0.00
P/FCF Ratio-18.45
Enterprise Value/Market Cap3.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-61.30
Enterprise Value/Ebitda1.06
Forecast
1Y Price Target
$27.00Price Target Upside225.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.54
Revenue Forecast (FY)$92.15M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe statistically significant HOPE-3 primary endpoint provides the lead program with direct clinical evidence in Duchenne muscular dystrophy. If confirmed through regulatory review, demonstrated preservation of upper-limb function could support meaningful patient value and a durable basis for commercialization.
Clinical Evidence And SafetyBroad patient exposure across multiple trials and extended treatment periods creates a meaningful clinical and safety database. This experience can strengthen physician confidence, support regulatory discussions, and reduce uncertainty around ongoing administration of the cell therapy.
Manufacturing ReadinessOperational in-house GMP manufacturing gives Capricor direct control over an important part of the development and launch process. That capability can support supply preparation, preserve execution flexibility, and reduce the distance between regulatory approval and potential commercialization.
Bears Say
Regulatory DelayThe FDA's major-amendment classification and three-month review extension delay a potential decision and prolong the period before commercial revenue could begin. The added review also signals that the regulatory package requires further assessment, increasing approval timing and execution uncertainty.
Indication RiskThe strongly negative advisory committee vote weakens the original cardiomyopathy approval case, even though the recommendation is non-binding. A narrower or delayed indication could reduce the initial addressable opportunity and require Capricor to refine its regulatory and commercial strategy.
Persistent Cash BurnSustained negative operating and free cash flow show that the company is not yet funding operations internally. Continued burn increases reliance on financing or future commercial progress, while limiting flexibility to absorb delays, fund pipeline work, or expand investment without additional capital.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $2.96 and its highest was $40.37 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is $390.11M.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 28 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.589 by -$0.111.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 58,138,990 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.589. Following the earnings report the stock price went up 57.957%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in CAPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.00 (225.69% Upside)
$27.00 (225.69% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 84%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 14.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.92%
12-Months-Change
Fundamentals
Return on Equity
-56.60%
Trailing 12-Months
Asset Growth
176.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
CAPR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful clinical and regulatory progress (Lancet publication, statistically significant primary HOPE‑3 endpoint for upper limb function, established safety exposure, operational in‑house manufacturing and $237.9M cash) against substantial near‑term challenges (AdCom vote against the cardiomyopathy question, mixed secondary endpoint results, no revenue, rising operating expenses and widening losses, a Form 483 observation, paused non‑Daramycin pipeline work, and an ongoing commercial dispute with NS Pharma). Management has a clear path to submit an amendment focused on the primary skeletal muscle indication and the FDA indicated willingness to review it, but regulatory and financial risks remain in the near term.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$27.00
▲(225.69% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Abeona Therapeutics
―
RegenXBio
―
Solid Biosciences
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.93% Insiders
8.15% Mutual Funds
0.01% Other Institutional Investors
78.58% Public Companies and Individual Investors